Phase of Development: In Vivo Proof of Concept

Mechanism of Action: Tau Proteostasis, Propagation and Clearance

Compound Type/Modality: Small Molecule

Small molecule autophagy modulators for tauopathies

David Rubinsztein, MB ChB, BSc(Med), PhD

Deputy Director, Cambridge Institute for Medical Research
Professor of Molecular Neurogenetics, University of Cambridge
UK Dementia Research Institute Group Leader

For further information about this program Contact: